Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention
NCT04273061Phase 2Recruiting
- Sponsor
- BC Cancer
- Start
- Jun 2020
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in breast cancer, lung cancer, gastrointestinal cancer and 6 more (3 cohorts), sponsored by BC Cancer. Primary endpoint: Overall Response Rate at 54 months. Started Jun 2020; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
breast cancerlung cancergastrointestinal cancergenitourinary cancergynecologic cancer
Beyond the preview
Go deeper on NCT04273061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04273061.